395 W 12th Ave
Columbus, OH 43210
Phone: (614) 293-4997
Assistant Professor-Clinical, Nephrology
Immunopathology;Internal Medicine;Nephrology;Regenerative medicine
Since I have an extensive laboratory research background before my clinical carreer, my initial intent when I came to OSU in 2005, was to spend more time doing laboratory research on the traditional tenure track. I have since changed to the clinical track and redirected my efforts toward more translational research, applying my basic science experience toward clinical studies.
I have already completed four multicenter clinical trials as the site principal investigator since coming to OSU, and hope to keep the ball rolling. The two most important areas of transplant renal failure to me remain delayed graft function (DGF; similar to acute kidney injury), and antibody rejection, and I continue to pursue study of these processes with the hope of improving them.
While novel therapies often require novel drugs, sometimes it only requires novel approaches of current therapy. I have recently applied for an IND application for the use of an already FDA approaved drug, Belatacept, in the management of DGF.
I have already attained FDA approval for proceeding with my investigator initiated DGF protocol under my own IND application, and currently await our own institutional IRB application and budgetary approval from Bristol-Myers Squibb to move forward. I find that I am most excited to be applying therapy at the patient level in a translational than staying at the benchside. To date, there has yet been a successful attempt at improving DGF outcomes, and the Belatacept trial has the potential for a landmark study.
In a second, yet to be funded clinical trial, I am working with collaborators across several disciplines to evaluate a novel biological detection process using immunologically modified field-effect transistors. These have the potential to detect picomolar levels of inflammatory citokines that might be used to diagnose rejection in biologic fluids.
Despite dwindling NIH support for research, I have been resourceful enough to have had some reasonable success in bringing and completing clinical/translational studies here at OSU. While industry sponsored studies appear to be the growing trend, I still intend to compete for the limited remaining NIH funds.
My national reputation has been growing slower than anticipated, since completing my fellowship at Mass. General Hospital. However, I am recognized within my field and have continued to develop National exposure through presenations and multicenter trial participation that garner important resources for future development. As one of the largest national kidney transplant centers, OSU has the potential to provide significant resources for career development, in both patient volume for clinical experience as well as data collection for clinical trials. This is why I came to OSU.
|2012||anthony alvarado, The Ohio State University. Graduated 2013.|
|2007 - 2008||Fawn Langerman, The Ohio State University. Graduated 2008.|
Studies Relating to Neural Regeneration: 1. A Neurite-Promoting Factor Derived From Striated Muscle, and 2. Differentiation of Progenitor Cells for Newborn Rat Forebrain.
|1999 - present||MD: American Board of Internal Medicine|
|2004 - present||MD: American Board of Internal Medicine|
|2005 - present||MD: State Medical Board of Ohio|
|06/01/2005||Attending, Assistant Professor (clinical) (The Ohio State University)|
A new endothelial progenitor cell flow-based method for donor-recipient cross-making detects donor-specific endothelial antigens.
Prolonged early graft dysfunction with sirolimus and association with mortality in renal transplant recipients.
Recurrence of IgA Nephropathy Post Kidney Transplantation in Steroid Free vs. Steroid Dependent Immunosuppression Protocol.
Response to Therapy and Predictors of Graft Survival in Antibody Mediated Rejection
Examination of Infectious Complications with Plasmapheresis in Combination with Anti-Thymocycte Globulin for the Treatment of Acute Rejection.
Tolerance of ACE-Inhibitor/ARB Use Post Renal Transplant.
Immunologically Modified FETs for Protein Detection in Biologic Fluids.
|1986||B.S., UCLA Los Angeles California|
|1988||M.S., UCLA Los Angeles California|
|1996||M.D./Ph.D., University of Maryland|
|2006 - present||arthritis and rheumatism|
|2008 - present||clinical nephrology|
|2010 - present||Transplantation|
|2012 - present||Ibnosina|
|2010 - 2012||Certificate of Excellence in Patient Service. The Ohio State Unviversity Wexner Medical Center.|
|January 1986||Ruettinger, R T., J. Von Visger, A.J. Fulco."Relative Induction of Three Distinct Cytochrome P-450 Species in Twelve Strains of Bacillus Megaterium" .|
|January 1993||Von Visger, J., T.H. Oh, D.S. Yeon, G.J. Markelonis."Maturation of CNS Stem Cells from New Born Rat Forebrain in a Defined Medium" .|
|January 1995||Oh, T H; G. Markelonis, J. Von Visger, B. Baik, M.T. Shipley, M T."Acidic pH Increases Immunoreactivity of GFAP in Cultured Rat Astrocytes" .|
|June 2005||Linde, P., J. Von Visger, K. Maxwell, J. Brotherton, C. Conlin, A.B. Cosimi, W.W. Williams."Enhancing In Vitro Clearance of Small Molecule Toxins Using a Novel CVVH-Based Recirculation Loop: Implicationsfor Bioartificial Liver Support Systems and Renal Replacement Therapies" .|
|January 2006||Pesavento, T., E. Davies, J. Von Visger, U. Nori, B. Miller, R.M. Ferguson."Randomized, Prospective Prednisone Withdrawl Trial in Kidney Transplant Patients Treated with Mycophenolate Sodium Comparing Rapamycin vs C2 Dosed Cyclosporine" .|
|January 2007||Von Visger, J., T. Pesavento, U. Nori."Increased Mortality Risk For Renal Transplant Recipients On Sirolimus And Delayed Graft Function: A Review of 74,000 Patients" .|
|October 2007||Dipaola, N., J. Von Visger, P. Adams."Acute Humoral Rejection Mediated By Donor Specific Anti-Endothelial Antibodies Detected Using XM-One" .|
|January 2007||Von Visger, J., P. Adams, N. Dipaola."A New Endothelial Progenitor Cell Flow-Based Method For Donor-Recipient Cross-Matching Detects Donor-Specific Endothelial Antigens" .|
|January 2007||Von Visger, J., T. Pesavento, U. Nori."Prolonged Early Graft Dysfunction With Sirolimus And Association With Mortality In Renal Transplant Recipients" .|
|May 2007||Pesavento T., U. Nori, J. Von Visger, M. Henry, R. Ferguson."Sirolimus, Independent Of Cyclosporine, Is Associated With Worsened Proteinuria In Renal Transplantation" .|
|August 2008||Zachary, A. A Jackson, J. Melancon, M. Breimer, L. Ryderberg, J. Von Visger, R. Pelletier, S. Saidman, W.W. Williams, G. Klintmalm, S. Coultrup, J. Holgersson, G. Tyden, S. Holgersson, P. Grufman."Final Clinical Trial Data Evaluating The XM-One Endothelial Crossmatch Test In Predicting Early Rejection Episodes in Renal Allograft Recipients." .|
|May 2008||Von Visger J., K. Porter, L. Yu."Review of 90,866 Renal Transplants: Survival Impact of Sirolimus" .|
|May 2008||Nori, U.S., T. Pesavento, E. Davies, J. Von Visger, B. Miller, R. M. Ferguson."Randomized Prospective Prednisone Withdrawl Trial In kidney Transplant Patients Treated with Sirolimus vs. Microemulsified Cyclosporine Based Regimens" .|
|January 2009||Humes H D, Dillon J, Tolwani AJ, Cremisi H, Wali R, Murray P, Ye J, Chawla LS, Vijayan A, Finkel, KW Kraus,M, Atta M, Von Visger J, Block GA, Charytan D, and Vinnikova AK."A Novel Selective Cytopheretic Inhibitory Device (SCD) Improves Mortality in ICU Patients With Acute Kidney Injury (AKI) and Multiorgan Failure (MOF) In a Phase II Clinical Study" .|
|April 2010||Parikh, S, Gunay, Y, Srinivas, S, Shah, R, Von Visger, J, Nori, U, Rajab, A, Pesavento, T, Sing."Cardiac Stress Test as a Risk Stratification Tool for Early Post Kidney Transplant Cardiovascular Outcomes in Diabetic ESRD Patients" . : 306|
|May 2012||Nori, U, Shah, R, Haddad, N, Von Visger, J, Agarwal, A."Management of Renal Transplant Recipients with Failing Alolgrafts and Transitioning to Renal Replacement Therapy" . : 493|
|April 2012||Alvarado, A, Casal, P, Theiss, A, Wang, Y, Hadley, G, Singh, N, Brillson, L, Pelletier, R, Lu, W, Lee, S, and Von Visger, J."Monitoring of Transplant Graft Status by Immunologically Modified Field Effect Transistors" .|
|May 2012||Wier, M, Vincenti, F, Von Visger, J, Kopyt, N, Mannon, R, Tseng, S, Goodman, W, and Wolf, M.."Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients: A Propspective Cohort Study" .|
|May 2012||Vincenti, F, Weir, Von Visger, J, et al."A Prospective Cohort Study of Persistent Hyperparathyroidism in Kidney Transplant Recipients" . : 8-8|
|May 2012||Andreoni, K, Elkhammas, E, Rajab, A, Pelletier, R, Bumgardner, G, Forbes, R, Singh, N, Von Visger, J, Pesavento, T, Davies, E, Nori, U, Henry, M."Influence of BMI and Age on Simultaneous Kidney-Pancreas Recipients" .|
|April 2013||Hulbert, A, Rajab, A, Von Visger, J, Winters, H."Examination of Infectious Complications with Plasmapheresis in Combination with Anti-Thymocyte Globulin for the Treatment of Acute Rejection" . : 330|
|April 2013||Hulbert, A, Rajab, A, Von Visger, J and Winters, H."Examination of Infectious Complications with Plasmapheresis in Combination with Ant-Thymocyte Globulin for the Treatment of Acute Rejection" . : 330|
|April 2013||Pelletier, R, Von Visger, J, Adams, P, and Henry, M."The Outcome of Luminex Single Antigen Bead DSA Detection in Post-Transplant Alloantibody Producing Recipients Does Not Correlate with Differential Graft Loss" . : 418-19|
Kidney Precursor Stem Cells Flk1+, Sca-1+
Review of 90,886 renal transplants: Survival impact of sirolimus
|present||volunteer. Upper Arlington School systems. upper arlington, OH.|
|present||consultant. AmGen. Thousand Oaks, CA.|
|2006 - present||volunteer kidney screening. National Kidney Foundation. Columbus, OH.|
|2011 - present||Judge volunteer. The Ohio State University. Columbus, OH.|
|2013||volunteer. Denman Forum. Columbus, OH.|